top of page

Content Rheum

Interleukin-23 Inhibition

FAQs

Click a title to watch the FAQ

Define, compare, and contrast humoral and cell-mediated immunity

Describe the IL23/IL17 axis

What is the role of the IL23/IL17 axis in rheumatic disease?

Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.

Why is Binding CD64+ Important When Discussing IL23 Directed Therapy

How does axial PsA differ from AS clinically, genetically, and radiographically

How do you interpret radiographic progression using modified-vdHS or mTSS?

How does real-world evidence differ from randomized controlled trials?

How Do You Interpret cDAPSA/DAPSA and MDA?

Medication Review_v2.png

MEDICATION REVIEWS

Click a title to watch the review

Describe the mechanism of action of guselkumab

What is Non-Responder Imputation and How is it Utilized in Clinical Trials

How is Guselkumab dosed in PsO, PsA, and IBD

What is the safety profile of guselkumab in PsO and PsA?

JOURNAL CLUBS

Click a title to read the journal

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Long-Term Guselkumab Safety in Psoriasis & PsA (Phase II/III Analysis)

PODCASTS

Click a title to play the podcast

The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD

CD64+ Binding: Description, Relevance, and Potential Clinical Implications

The Clinical Utility of Guselkumab in Axial PsA

Become a RhAPP Member

bottom of page